Related references
Note: Only part of the references are listed.What's New in the Treatment of Systemic Lupus Erythematosus
Stamatis Nick Liossis et al.
FRONTIERS IN MEDICINE (2021)
GENERATION OF PT101, A HIGHLY SELECTIVE IL-2 MUTEIN FOR TREATMENT OF AUTOIMMUNE DISEASES
J. Visweswaraiah et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Follicular Regulatory T Cells in Systemic Lupus Erythematosus
Xin Xia et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2021)
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases
Neha Dixit et al.
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2021)
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair
Ian C. Boothby et al.
SCIENCE IMMUNOLOGY (2020)
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
Guillermo Ruiz-Irastorza et al.
RHEUMATOLOGY (2020)
Emerging targets for the treatment of lupus erythematosus: There is no royal road to treating lupus
Shinsuke Yasuda
MODERN RHEUMATOLOGY (2019)
New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases
Le Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
Michelle Rosenzwajg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Helios+ and Helios- Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires
Angela M. Thornton et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial
Jens Y. Humrich et al.
LANCET RHEUMATOLOGY (2019)
Fine tuning subsets of CD4(+) T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases
Zhen Zhao et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus
Masayuki Mizui et al.
FRONTIERS IN IMMUNOLOGY (2018)
Revisiting IL-2: Biology and therapeutic prospects
Abul K. Abbas et al.
SCIENCE IMMUNOLOGY (2018)
Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus
Jyoti Bakshi et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
Caroline von Spee-Mayer et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies
V. Jucaud et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease
John Koreth et al.
BLOOD (2016)
T cells in Systemic Lupus Erythematosus
Abel Suarez-Fueyo et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Restoring regulation - IL-2 therapy in systemic lupus erythematosus
Jens Y. Humrich et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
Jing He et al.
NATURE MEDICINE (2016)
Systemic lupus erythematosus
Arvind Kaul et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
FOXP3+ regulatory T cells and their functional regulation
Zhiyuan Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2015)
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
David Klatzmann et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy
Frederic Van Gool et al.
BLOOD (2014)
Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
Sawa Ito et al.
MOLECULAR THERAPY (2014)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation
Allison L. Bayer et al.
IMMUNOLOGIC RESEARCH (2013)
The pathogenesis of systemic lupus erythematosus-an update
Jinyoung Choi et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Abnormalities of B cell subsets in patients with systemic lupus erythematosus
Thomas Doerner et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
David Saadoun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
FOXP3+ regulatory T cells in the human immune system
Shimon Sakaguchi et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue
Georg Wieczorek et al.
CANCER RESEARCH (2009)
A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells
Aixin Yu et al.
IMMUNITY (2009)
Mechanisms of disease: Systemic lupus erythematosus
Anisur Rahman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice:: implications for the nonredundant function of IL-2
TR Malek et al.
IMMUNITY (2002)
Human natural killer cells:: a unique innate immunoregulatory role for the CD56bright subset
MA Cooper et al.
BLOOD (2001)
Share Paper
